BOYDSense awarded by the DCB Innovation Challenge 2022 Expert Jury

BOYDSense SAS, subsidiary of Alpha MOS (Euronext Paris, ISIN: FR0013421286 ALNEO), announces that they have been recognized and awarded in the category “diabetes devices” from the DCB Innovation Challenge 2022.

Held every year, the DCB Open Innovation Challenge aims at fostering new initiatives and innovative projects in the domain of diabetes management.
BOYDSense breath-based glucose monitoring device competed alongside 70 projects from 22 countries in the 2022 edition.
BOYDSense project successfully passed the first selection step and was among the 3 finalists presenting their work during the Start-Up Night and Award Ceremony end of November.
At the end of the Challenge, the Expert Jury, composed of leading scientists, leading Health Care Professionals and Patients living with Diabetes, decided to award BOYDSense with a financial reward.
Ben Delhey, CEO of BOYDSense, comments: “We feel honored and proud to be awarded from the DCB Innovation Challenge 2022 leading expert jury for our work we do to develop a non-invasive health monitoring platform to monitor chronic diseases, starting with Diabetes.
This distinction will also open us new networking and collaboration perspectives and leverage the development of our breath-based glucose monitoring device.”

About BOYDSense

BOYDSense, Inc. is a medical technology company developing affordable, non-invasive tools for measuring critical biomarkers via exhaled breath. Its mission is to build the platform for anywhere, anytime biosignature capture and display to help consumers better manage their conditions. Breath-based metabolomics focuses on the capture, identification, and quantification of volatile organic compound (VOC) biomarker patterns in human breath and using them to diagnose and monitor chronic diseases, such as diabetes. The BOYDSense platform will also allow consumers and healthcare providers to use breath as a non-invasive medium to detect and monitor diseases like cancer, obesity, asthma, and others. BOYDSense’s first product under development, the g-Sense Breath Meter, is an affordable handheld device that allows people with diabetes to accurately measure blood glucose values through breath-based VOCs without the cost, pain, and social stigma associated with conventional fingerstick glucose testing. BOYDSense is an Alpha MOS company, the leader in volatile organic compound analysis.

For more information, please visit: